AZ12080282 | 1126367-99-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: AZ12080282
• 英文别名: N-(5-(1H-imidazol-2-yl)-2-methylphenyl)-4-(pyridin-2-ylmethoxy)benzamide；N-[5-(1H-imidazol-2-yl)-2-methylphenyl]-4-(pyridin-2-ylmethoxy)benzamide
• CAS: 1126367-99-4
• 化学式: C₂₃H₂₀N₄O₂
• 分子量: 384.437
• InChiKey: KMSKKYBHDQYHMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  79.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氨基-4-甲基苯硼酸 在 四(三苯基膦)钯 、 caesium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 65.67h， 生成 AZ12080282
  参考文献：
  名称：

  Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO

  摘要：

  Cell-based subset screening of compounds using a Gli transcription factor reporter cell assay and shh stimulated cell differentiation assay identified a series of bisamide compounds as hedgehog pathway inhibitors with good potency. Using a ligand-based optimization strategy, heteroaryl groups were utilized as conformationally restricted amide isosteres replacing one of the amides which significantly increased their potency against SMO and the hedgehog pathway while decreasing activity against p38 alpha kinase. We report herein the identification of advanced lead compounds such as imidazole 11c and 11f encompassing good p38 alpha selectivity, low nanomolar potency in both cell assays, excellent physiochemical properties and in vivo pharmacokinetics. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.104

文献信息

• [EN] HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS<br/>[FR] AMIDES HÉTÉROCYCLIQUES UTILES DANS LE TRAITEMENT DU CANCER ET DU PSORIASIS
  申请人：ASTRAZENECA AB

  公开号：WO2009027746A1

  公开（公告）日：2009-03-05

  The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. Formula (IA) with the provisio that either R2or R3 is (Z).

  本公开涉及杂环酰胺化合物，这些化合物对抑制Hedgehog途径有用，并且它们在治疗由Hedgehog途径抑制单独或部分介导的疾病或医疗状况中的用途。还公开了这些化合物的制造方法，包括这些化合物的药物组合物，以及利用这些化合物制造用于治疗受试者中的这些疾病和医疗状况的药物的方法。公式（IA），条件是R2或R3中的一个是（Z）。
• HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS
  申请人：Dakin Leslie

  公开号：US20100311748A1

  公开（公告）日：2010-12-09

  The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. Formula (IA) with the provisio that either R 2 or R 3 is (Z).

  本公开涉及杂环酰胺化合物，其用于抑制Hedgehog途径，并在治疗由Hedgehog途径抑制单独或部分介导的疾病或医疗状况中发挥作用。还公开了这些化合物的制造方法，包括这些化合物的制药组合物以及这些化合物在制造用于治疗主体中的这些疾病和医疗状况的药物中的用途。公式（IA），其中R2或R3为（Z）的情况。
• [EN] COMBINATIONS OF MEK AND HH INHIBITORS<br/>[FR] COMBINAISONS D'INHIBITEURS DE MEK ET DE HH
  申请人：ASTRAZENECA AB

  公开号：WO2011095807A1

  公开（公告）日：2011-08-11

  The present invention relates to a therapeutic combination comprising a MEK inhibitor and an HH- pathway inhibitor, and to methods for the production of an anti- cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to: a therapeutic combination comprising a MEK inhibitor and an HH- pathway inhibitor; a combination product comprising a MEK inhibitor and an HH- pathway inhibitor, a kit of parts comprising a MEK inhibitor and an HH- pathway inhibitor; use of a therapeutic combination, combination product or kit of parts in the treatment of cancer; a method of treating cancer comprising administering the therapeutic combination, combination product or kit of parts to a patient. The therapeutic combination and methods of the invention are also useful in the treatment of conditions in which the inhibition of MEK and/or the HH-pathway is beneficial.
• Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO
  作者：Bin Yang、Alexander W. Hird、Daniel John Russell、Benjamin P. Fauber、Les A. Dakin、Xiaolan Zheng、Qibin Su、Robert Godin、Patrick Brassil、Erik Devereaux、James W. Janetka

  DOI：10.1016/j.bmcl.2012.04.104

  日期：2012.7

  Cell-based subset screening of compounds using a Gli transcription factor reporter cell assay and shh stimulated cell differentiation assay identified a series of bisamide compounds as hedgehog pathway inhibitors with good potency. Using a ligand-based optimization strategy, heteroaryl groups were utilized as conformationally restricted amide isosteres replacing one of the amides which significantly increased their potency against SMO and the hedgehog pathway while decreasing activity against p38 alpha kinase. We report herein the identification of advanced lead compounds such as imidazole 11c and 11f encompassing good p38 alpha selectivity, low nanomolar potency in both cell assays, excellent physiochemical properties and in vivo pharmacokinetics. (C) 2012 Elsevier Ltd. All rights reserved.